In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%.
@oncoalert.bsky.social
@oncbrothers.bsky.social
@erplimackmd.bsky.social
doi.org/10.1200/JCO-...
In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%.
@oncoalert.bsky.social
@oncbrothers.bsky.social
@erplimackmd.bsky.social
doi.org/10.1200/JCO-...
By: WBBJ 7 Eyewitness News Staff on Saturday, December 20, 2025
By: WBBJ 7 Eyewitness News Staff on Saturday, December 20, 2025